272 related articles for article (PubMed ID: 25250521)
1. Dietary methionine restriction inhibits prostatic intraepithelial neoplasia in TRAMP mice.
Sinha R; Cooper TK; Rogers CJ; Sinha I; Turbitt WJ; Calcagnotto A; Perrone CE; Richie JP
Prostate; 2014 Dec; 74(16):1663-73. PubMed ID: 25250521
[TBL] [Abstract][Full Text] [Related]
2. High animal fat intake enhances prostate cancer progression and reduces glutathione peroxidase 3 expression in early stages of TRAMP mice.
Chang SN; Han J; Abdelkader TS; Kim TH; Lee JM; Song J; Kim KS; Park JH; Park JH
Prostate; 2014 Sep; 74(13):1266-77. PubMed ID: 25053105
[TBL] [Abstract][Full Text] [Related]
3. Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model.
Raina K; Blouin MJ; Singh RP; Majeed N; Deep G; Varghese L; Glodé LM; Greenberg NM; Hwang D; Cohen P; Pollak MN; Agarwal R
Cancer Res; 2007 Nov; 67(22):11083-91. PubMed ID: 18006855
[TBL] [Abstract][Full Text] [Related]
4. An investigation of the effects of late-onset dietary restriction on prostate cancer development in the TRAMP mouse.
Suttie AW; Dinse GE; Nyska A; Moser GJ; Goldsworthy TL; Maronpot RR
Toxicol Pathol; 2005; 33(3):386-97. PubMed ID: 15805078
[TBL] [Abstract][Full Text] [Related]
5. Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice.
Gupta S; Ahmad N; Marengo SR; MacLennan GT; Greenberg NM; Mukhtar H
Cancer Res; 2000 Sep; 60(18):5125-33. PubMed ID: 11016639
[TBL] [Abstract][Full Text] [Related]
6. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
Narayanan BA; Narayanan NK; Pittman B; Reddy BS
Clin Cancer Res; 2004 Nov; 10(22):7727-37. PubMed ID: 15570007
[TBL] [Abstract][Full Text] [Related]
7. Epigallocatechin-3-Gallate suppresses early stage, but not late stage prostate cancer in TRAMP mice: mechanisms of action.
Harper CE; Patel BB; Wang J; Eltoum IA; Lamartiniere CA
Prostate; 2007 Oct; 67(14):1576-89. PubMed ID: 17705241
[TBL] [Abstract][Full Text] [Related]
8. A null-mutation in the Znt7 gene accelerates prostate tumor formation in a transgenic adenocarcinoma mouse prostate model.
Tepaamorndech S; Huang L; Kirschke CP
Cancer Lett; 2011 Sep; 308(1):33-42. PubMed ID: 21621325
[TBL] [Abstract][Full Text] [Related]
9. E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse.
Wechter WJ; Leipold DD; Murray ED; Quiggle D; McCracken JD; Barrios RS; Greenberg NM
Cancer Res; 2000 Apr; 60(8):2203-8. PubMed ID: 10786685
[TBL] [Abstract][Full Text] [Related]
10. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP).
Mentor-Marcel R; Lamartiniere CA; Eltoum IE; Greenberg NM; Elgavish A
Cancer Res; 2001 Sep; 61(18):6777-82. PubMed ID: 11559550
[TBL] [Abstract][Full Text] [Related]
11. Oral grape seed extract inhibits prostate tumor growth and progression in TRAMP mice.
Raina K; Singh RP; Agarwal R; Agarwal C
Cancer Res; 2007 Jun; 67(12):5976-82. PubMed ID: 17575168
[TBL] [Abstract][Full Text] [Related]
12. Cancer progression in the transgenic adenocarcinoma of mouse prostate mouse is related to energy balance, body mass, and body composition, but not food intake.
Huffman DM; Johnson MS; Watts A; Elgavish A; Eltoum IA; Nagy TR
Cancer Res; 2007 Jan; 67(1):417-24. PubMed ID: 17185379
[TBL] [Abstract][Full Text] [Related]
13. Anti-inflammatory therapies in TRAMP mice: delay in PCa progression.
Kido LA; Montico F; Sauce R; Macedo AB; Minatel E; Costa DB; Carvalho JE; Pilli RA; Cagnon VH
Endocr Relat Cancer; 2016 Apr; 23(4):235-50. PubMed ID: 26772819
[TBL] [Abstract][Full Text] [Related]
14. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Kaplan PJ; Mohan S; Cohen P; Foster BA; Greenberg NM
Cancer Res; 1999 May; 59(9):2203-9. PubMed ID: 10232609
[TBL] [Abstract][Full Text] [Related]
15. Androgen-independent prostate cancer progression in the TRAMP model.
Gingrich JR; Barrios RJ; Kattan MW; Nahm HS; Finegold MJ; Greenberg NM
Cancer Res; 1997 Nov; 57(21):4687-91. PubMed ID: 9354422
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of MUC18 correlates with the metastatic progression of mouse prostate adenocarcinoma in the TRAMP model.
Wu GJ; Fu P; Chiang CF; Huss WJ; Greenberg NM; Wu MW
J Urol; 2005 May; 173(5):1778-83. PubMed ID: 15821586
[TBL] [Abstract][Full Text] [Related]
17. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
[TBL] [Abstract][Full Text] [Related]
18. Genistein alters growth factor signaling in transgenic prostate model (TRAMP).
Wang J; Eltoum IE; Lamartiniere CA
Mol Cell Endocrinol; 2004 Apr; 219(1-2):171-80. PubMed ID: 15149738
[TBL] [Abstract][Full Text] [Related]
19. Methionine restriction decreases visceral fat mass and preserves insulin action in aging male Fischer 344 rats independent of energy restriction.
Malloy VL; Krajcik RA; Bailey SJ; Hristopoulos G; Plummer JD; Orentreich N
Aging Cell; 2006 Aug; 5(4):305-14. PubMed ID: 16800846
[TBL] [Abstract][Full Text] [Related]
20. Insulin-Like growth factor 1 related pathways and high-fat diet promotion of transgenic adenocarcinoma mouse prostate (TRAMP) cancer progression.
Xu H; Jiang HW; Ding Q
Actas Urol Esp; 2015 Apr; 39(3):161-8. PubMed ID: 25442907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
